tiprankstipranks
Advertisement
Advertisement

KYTX Stock Latest News

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
Market News3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/23/2026
7d ago
ALT
BTBT
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
PremiumRatings
Kyverna Therapeutics: Strong CAR‑T Efficacy and Safety in SPS and gMG Underpin Buy Rating and $20 Target
7d ago
KYTX
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
PremiumCompany Announcements
Kyverna announces strong Phase 2/3 CAR T neuroimmunology data
8d ago
8K
KYTX
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
PremiumCompany Announcements
Kyverna Reports Positive Phase 2 Data in Stiff Person Syndrome
8d ago
8K
KYTX
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
PremiumThe Fly
Kyverna Therapeutics reports ‘positive’ results from KYSA-8 trial of miv-cel
9d ago
KYTX
Kyverna Therapeutics: Strengthened Buy Rating on Robust Miv-cel Data and Reduced Regulatory Risk in gMG
PremiumRatingsKyverna Therapeutics: Strengthened Buy Rating on Robust Miv-cel Data and Reduced Regulatory Risk in gMG
9d ago
KYTX
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
Premium
The Fly
Kyverna Therapeutics presents longer-term Phase 2 data for Miv-cel
10d ago
KYTX
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
Premium
Company Announcements
Kyverna Reports Positive Phase 2 Data in Myasthenia Gravis
10d ago
8K
KYTX
Kyverna Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Kyverna Therapeutics files $300M mixed securities shelf
1M ago
KYTX
Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)
PremiumThe Fly
Kyverna Therapeutics reports Q4 EPS (80c), consensus (86c)
1M ago
KYTX
Kyverna Therapeutics Strengthens Board With New Director Appointments
PremiumCompany Announcements
Kyverna Therapeutics Strengthens Board With New Director Appointments
2M ago
8K
KYTX
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
PremiumThe Fly
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
2M ago
BEAM
KYTX
Kyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
PremiumCompany AnnouncementsKyverna Therapeutics Appoints New CTO to Drive CAR-T Manufacturing
3M ago
8K
KYTX
Kyverna Therapeutics appoints Pujols as Chief Technology Officer
Premium
The Fly
Kyverna Therapeutics appoints Pujols as Chief Technology Officer
3M ago
KYTX
Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
Premium
Ratings
Kyverna Therapeutics: Strong Early Autoimmune CAR-T Data, Accelerated SPS Timeline, and Solid Cash Runway Support Buy Rating
4M ago
KYTX
Kyverna Therapeutics Names Christi Shaw Executive Board Chair
PremiumCompany Announcements
Kyverna Therapeutics Names Christi Shaw Executive Board Chair
4M ago
8K
KYTX
Kyverna Therapeutics provides corporate update, priorities for 2026
PremiumThe Fly
Kyverna Therapeutics provides corporate update, priorities for 2026
4M ago
KYTX
Kyverna Therapeutics Announces $100 Million Public Offering
PremiumCompany Announcements
Kyverna Therapeutics Announces $100 Million Public Offering
4M ago
8K
KYTX
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
PremiumThe Fly
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
4M ago
PG
ABM
Kyverna prices 13.3M shares at $7.50 in underwritten public offering
PremiumThe FlyKyverna prices 13.3M shares at $7.50 in underwritten public offering
4M ago
KYTX
Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo
Premium
The Fly
Kyverna Therapeutics price target raised to $33 from $31 at Wells Fargo
5M ago
KYTX
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
5M ago
IMNM
KYTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >